Eusa Pharma completes $115m acquisition of Sylvant for iMCD treatment

Eusa Pharma has successfully acquired the global rights to Sylvant (siltuximab), a drug used in the treatment of idiopathic multicentric Castleman’s disease (iMCD), from Janssen ... Read More